Iomeprol versus iopamidol in contrast-enhanced computed tomography of thoracic and abdominal organs.

The aim of this double-blind, parallel-group study was to compare the safety, tolerance, and efficacy of iomeprol-350 (350 mgI/ml), iomeprol-400 (400 mgI/ml) and iopamidol-370 (370 mgI/ml) for use in contrast-enhanced body computed tomography (CT). Following written informed consent, 120 adult inpatients of either sex requiring CT of thoracic or abdominal organs were randomly assigned to receive iomeprol-350, iomeprol-400 or iopamidol-370. Pre- and post-contrast, all patients underwent clinical, instrumental and laboratory investigation to assess the safety of the test agents. Tolerance was assessed in terms of discomfort associated with contrast injection. Two experienced radiologists independently and blindly graded the quality of contrast enhancement obtained with the different contrast solutions by means of a five-point ordinal scale as follows: 1, insufficient; 2, sufficient; 3, good; 4, excellent; or E, excessive. Patients in the iomeprol groups needed fewer injections and a smaller volume of contrast medium to obtain examinations of adequate diagnostic quality. Contrast enhancement was judged as excellent or good in about 90% of the study examinations, without significant differences between the three study groups. During contrast injection, heat and pain sensations were minimal or absent in most cases. No serious adverse events occurred throughout the study. No significant changes in clinical, instrumental or laboratory safety parameters were observed. In conclusion, iomeprol-400 and iomeprol-350 appear to be contrast solutions at least as safe, well tolerated and effective as iopamidol-370 when used as contrast agents for body CT.

RCT Entities:   Population Interventions Outcomes